查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917710

数位PCR市场－2026年至2031年预测

Digital PCR Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

数位PCR市场预计将从2025年的981,865,000美元成长到2031年的2,151,540,000美元，复合年增长率为13.97%。

数位PCR (dPCR) 市场代表分子诊断和生命科学研究领域的一项重大技术进步，其精确度和绝对定量能力远超传统PCR方法。 dPCR透过将核酸样本分割成数千个独立的反应，无需标准曲线即可对目标DNA或RNA分子进行精确计数。这种向绝对定量模式转移正在推动dPCR在需要高灵敏度和高精度的应用领域中得到广泛应用，例如低频突变检测、拷贝数变异分析以及下一代定序结果的检验。肿瘤学、感染疾病监测和前沿研究领域对精确基因分析的需求不断增长，以及技术的持续进步，都推动了dPCR市场的扩张。

市场成长的主要驱动力是全球癌症和感染疾病率的不断上升，这使得对高灵敏度和高特异性诊断工具的需求日益增长。在肿瘤领域，数位PCR（dPCR）尤其适用于检测罕见突变、监测微量残存疾病（MRD）以及透过液态生物检体评估治疗效果。 dPCR能够从血液样本中精确量化肿瘤DNA，为患者后续观察提供了微创方法。同样，在感染疾病诊断方面，dPCR在检测低病毒量、精确量化病原体水平以及区分密切相关的病毒株方面具有卓越的灵敏度。随着临床对可靠定量数据以指导治疗决策的需求日益增长，dPCR正从研究工具发展成为精准医疗工作流程中不可或缺的一部分。

在数位PCR（dPCR）领域，液滴数位PCR（ddPCR）技术可望占据市场主导地位。此方法利用油包水乳液系统将样本分割成数万个奈米升级液滴，每个液滴都可作为独立的PCR微反应器。 ddPCR的主要优点包括：分割精度高、对复杂样本中存在的PCR抑制剂具有优异的耐受性，以及绝对定量方面的卓越准确性。这些特性使其特别适用于具有挑战性的临床应用，例如检测循环肿瘤DNA中的罕见突变和精确测量病毒量。整合式、易于使用的ddPCR系统的商业化，在推动这项先进技术从核心研究机构走向临床诊断实验室方面发挥了关键作用。

临床诊断领域是数位PCR (dPCR) 的主要且快速成长的应用领域。这一增长得益于dPCR相比定量PCR (qPCR) 具有更高的准确性、可重复性和灵敏度。 dPCR正越来越多地应用于非侵入性产前检测 (NIPT)、肿瘤生物标记检验以及难以培养或微量病原体的检测。个人化医疗的趋势以及对能够从有限或具有挑战性的样本类型中提供可靠结果的稳健检测方法的需求，正在加速诊断测试的开发及其在常规临床应用中的整合。

同时，基因工程和基因组学研究的不断扩展为数位PCR（dPCR）技术的应用创造了有利环境。在学术研究和生物製药领域，dPCR对于需要绝对定量分析的应用领域至关重要，例如检验基因编辑结果（如CRISPR-Cas9）、表征基因治疗中的病毒载体滴度以及进行精确的基因表现分析。该技术无需外部校准即可提供明确的拷贝数数据，使其成为生物製造和治疗药物开发中关键品管流程的黄金标准方法。基因组学研发投入的不断增加以及细胞和基因治疗的进步，正在持续推动对这些高精度分析工具的需求。

从区域来看，北美预计将继续保持在主导地位。这主要得益于该地区先进的医疗基础设施、许多大型生物技术和製药公司的集中布局，以及对基因组研究的大量投资。此外，该地区拥有许多先进诊断实验室，这些实验室积极采用创新技术，也进一步推动了市场成长。精准医疗的蓬勃发展，以及公共和私营部门对癌症和感染疾病研究的大量投入，共同建构了一个有利于dPCR技术开发和临床应用的强大生态系统。

竞争格局主要由成熟的生命科学仪器供应商和专业的分子诊断公司主导。主要参与企业的竞争优势体现在仪器的通量、灵敏度和易用性，以及包含专有试剂和分析软体的整合工作流程的开发。策略重点领域包括：拓展经临床检验的检测项目，提高自动化程度以简化高通量环境下的工作流程，以及与诊断实验室和生物製药公司合作，共同开发针对特定应用的解决方案。持续创新则着重于提升多重侦测能力、降低单样本成本，以及改善资料分析流程，进而简化临床使用者的解读。

总之，数位PCR市场正从一项专业研究技术转型为一项用于先进分子诊断的平台技术。其成长与临床和研究环境中对绝对定量分析日益增长的需求密切相关，与传统方法相比，数位PCR在准确性和灵敏度方面具有显着优势。未来市场趋势将受到以下因素的影响：进一步融入常规临床流程、开发标准化诊断检测方法以及持续创新以提高可及性和通量。随着精准医疗和数据驱动医疗的日益普及，数位PCR有望在疾病检测和监测以及个人化治疗策略的推进中发挥越来越重要的作用。

本报告的主要优势

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业及其他细分市场。
  • 竞争格局：了解全球主要参与企业的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索市场驱动因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，开发新的业务流和收入来源。
  • 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021-2025年实际数据及2026-2031年预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区分類的收入和预测评估，包括国家/地区
  • 公司概况（策略、产品、财务资讯）、重大发展等。

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依技术分類的数位PCR市场

  • 介绍
  • 液滴式数位PCR
  • 基于晶片的数位PCR
  • 光束式数位PCR

第六章 依应用分類的数位PCR市场

  • 介绍
  • 临床诊断
  • 法医学及其他
  • 研究

第七章 依产品类型分類的数位PCR市场

  • 介绍
  • 数位PCR系统
  • 耗材和试剂
  • 软体和服务

第八章 依最终用户分類的数位PCR市场

  • 介绍
  • 製药和生物技术产业
  • 临床检查室
  • 大学
  • 其他的

第九章 按地区分類的数位PCR市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Avance Biosciences
  • Bio-Rad Laboratories, Inc.
  • JN medsys
  • Sigma-Aldrich
  • Precigenome LLC
  • QIAGEN NV
  • STILLA TECHNOLOGIES
  • sysmex corporation
  • Thermo Fisher Scientific, Inc.

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615656

The digital PCR market is expected to expand at a 13.97% CAGR, reaching USD 2151.54 million in 2031 from USD 981.865 million in 2025.

The digital PCR (dPCR) market represents a significant technological advancement in molecular diagnostics and life science research, offering a level of precision and absolute quantification beyond traditional PCR methods. By partitioning a nucleic acid sample into thousands of individual reactions, dPCR enables the precise counting of target DNA or RNA molecules without the need for a standard curve. This paradigm shift towards absolute quantification is driving adoption in applications requiring high sensitivity and accuracy, including low-abundance mutation detection, copy number variation analysis, and validation of next-generation sequencing results. The market's expansion is fueled by the growing demand for precise genetic analysis in oncology, infectious disease monitoring, and advanced research, supported by continuous technological refinement.

A primary driver for market growth is the increasing prevalence of cancers and infectious diseases globally, which necessitates highly sensitive and specific diagnostic tools. In oncology, dPCR is particularly valuable for detecting rare mutations, monitoring minimal residual disease (MRD), and evaluating treatment response through liquid biopsy applications. Its ability to precisely quantify tumor DNA from a blood sample provides a less invasive method for longitudinal patient monitoring. Similarly, in infectious disease diagnostics, dPCR offers superior sensitivity for detecting low viral loads, quantifying pathogen levels with high accuracy, and distinguishing closely related strains. The clinical need for reliable, quantitative data to guide therapeutic decisions is elevating dPCR from a research tool to an integral component of precision medicine workflows.

Within the dPCR landscape, droplet digital PCR (ddPCR) technology is anticipated to hold a dominant market position. This method utilizes a water-oil emulsion system to partition samples into tens of thousands of nanoliter-sized droplets, each functioning as an independent PCR micro-reactor. The key advantages of ddPCR include its high degree of partitioning, robust resistance to PCR inhibitors present in complex samples, and exceptional precision for absolute quantification. These attributes make it especially suitable for challenging clinical applications such as detecting rare mutations in circulating tumor DNA or accurately measuring viral load. The commercialization of integrated, user-friendly ddPCR systems has been instrumental in translating this advanced technology from core research facilities into clinical diagnostic laboratories.

The clinical diagnostics segment represents a major and rapidly growing application area for dPCR. This growth is driven by the technology's superior accuracy, reproducibility, and sensitivity compared to quantitative PCR (qPCR). dPCR is increasingly employed for non-invasive prenatal testing (NIPT), oncology biomarker validation, and the detection of pathogens that are difficult to culture or present at very low concentrations. The trend toward personalized medicine and the need for robust assays that can deliver reliable results from limited or challenging sample types are accelerating its integration into diagnostic test development and routine clinical use.

Concurrently, the expanding scope of genetic engineering and genomic research is fostering a conducive environment for dPCR adoption. In academic and biopharmaceutical research, dPCR is essential for applications requiring absolute quantification, such as validating gene editing outcomes (e.g., CRISPR-Cas9), characterizing viral vector titers in gene therapy, and performing precise gene expression analysis. The technology's ability to provide unambiguous, copy-number data without external calibration makes it a gold-standard method for critical quality control steps in biomanufacturing and therapeutic development. The rising investment in genomic research and the development of cell and gene therapies are creating sustained demand for these high-precision analytical tools.

Geographically, North America is anticipated to maintain a leadership position in the dPCR market. This is attributed to the region's advanced healthcare infrastructure, high concentration of leading biotechnology and pharmaceutical companies, and substantial investment in genomic research. The presence of a sophisticated network of diagnostic laboratories that are early adopters of innovative technologies further supports market growth. A strong culture of precision medicine, coupled with significant research funding from both public and private sectors for cancer and infectious disease studies, creates a robust ecosystem for the development and clinical application of dPCR technologies.

The competitive landscape features established life science tool providers and specialized molecular diagnostics companies. Key players compete on the basis of instrument throughput, sensitivity, ease-of-use, and the development of integrated workflows that include proprietary reagents and analysis software. Strategic focus areas include expanding the menu of clinically validated assays, enhancing automation to streamline workflow in high-throughput settings, and forming partnerships with diagnostic labs and biopharmaceutical firms to co-develop application-specific solutions. Ongoing innovation is directed at improving multiplexing capabilities, reducing cost per sample, and enhancing data analysis pipelines to simplify interpretation for clinical users.

In conclusion, the digital PCR market is transitioning from a specialized research technology to a cornerstone of advanced molecular diagnostics. Its growth is fundamentally linked to the increasing demand for absolute quantification in both clinical and research settings, where its precision and sensitivity offer tangible advantages over conventional methods. The future trajectory of the market will be shaped by further integration into routine clinical pathways, the development of standardized diagnostic assays, and continued innovation to improve accessibility and throughput. As the emphasis on precise, data-driven healthcare intensifies, dPCR is poised to play an increasingly critical role in disease detection, monitoring, and the advancement of personalized therapeutic strategies.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Digital PCR Market Segmentation

  • By Technology
  • Droplet Digital PCR
  • Chip Based Digital PCR
  • Beaming Digital PCR
  • By Application
  • Clinical Diagnostics
  • Forensic and Others
  • Research
  • By Product Type
  • Digital PCR Systems
  • Consumables and Reagents
  • Software and Services
  • By End-User
  • Pharmaceuticals and Biotechnology Industries
  • Clinical Diagnostic Laboratories
  • Universities
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DIGITAL PCR MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Droplet Digital PCR
  • 5.3. Chip Based Digital PCR
  • 5.4. Beaming Digital PCR

6. DIGITAL PCR MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Clinical Diagnostics
  • 6.3. Forensic and Others
  • 6.4. Research

7. DIGITAL PCR MARKET BY PRODUCT TYPE

  • 7.1. Introduction
  • 7.2. Digital PCR Systems
  • 7.3. Consumables and Reagents
  • 7.4. Software and Services

8. DIGITAL PCR MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Pharmaceuticals and Biotechnology Industries
  • 8.3. Clinical Diagnostic Laboratories
  • 8.4. Universities
  • 8.5. Others

9. DIGITAL PCR MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Avance Biosciences
  • 11.2. Bio-Rad Laboratories, Inc.
  • 11.3. JN medsys
  • 11.4. Sigma-Aldrich
  • 11.5. Precigenome LLC
  • 11.6. QIAGEN N.V
  • 11.7. STILLA TECHNOLOGIES
  • 11.8. sysmex corporation
  • 11.9. Thermo Fisher Scientific, Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations